Kenalog 10 Injection triamcinolone acetonide is a steroid injected into the joint space to treat inflammation of the joints or tendons to treat arthritisbursitisor epicondylitis tennis elbow. Kenalog 10 is usually given in these conditions as a short-term treatment of a severe or aggravated episode. Kenalog 10 Injection is Glucose Thrombophlebitis injected into soft tissues of the body to treat certain skin disorders caused by autoimmune conditions such as lupusGlucose Thrombophlebitis, psoriasislichen planusand others.
Kenalog 10 Injection is available in generic form. Common side effects of Kenalog 10 include:. Dosage for Kenalog 10 Injection is individualized Verletzung von Plazentablut fließt 32 Wochen on the condition and patient response.
Kenalog 10 Injection may interact with aminoglutethimide, birth control pills, hormone replacement therapy, blood thinners, cyclosporine, digoxin, insulin or diabetes Glucose Thrombophlebitis you take by mouth, Glucose Thrombophlebitis, isoniazid, rifampin, seizure medication, antibiotics, aspirin, or other NSAIDs nonsteroidal anti-inflammatory drugs. Tell your doctor all medications you are taking, Glucose Thrombophlebitis. Kenalog 10 Injection should Glucose Thrombophlebitis used during pregnancy only if prescribed.
This medication may be harmful Glucose Thrombophlebitis a fetus. Infants born to mothers Glucose Thrombophlebitis have received corticosteroids during pregnancy should be observed for signs of hypoadrenalism.
This medication can pass into breast milk and may harm a nursing baby. Consult your doctor before breastfeeding. Our Kenalog 10 Injection triamcinolone acetonide Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. Glucose Thrombophlebitis emergency medical help if you have any of these signs of an allergic reaction: Tell your doctor about any unusual or bothersome side effect.
Anaphylactoid reaction, anaphylaxis including anaphylactic reactions and anaphylactic shockangioedema. Bradycardiacardiac arrest, cardiac arrhythmias, cardiac enlargement, circulatory collapse, congestive heart failurefat embolismhypertensionhypertrophic cardiomyopathy in premature infants, myocardial rupture following recent myocardial infarction see WARNINGSpulmonary edemasyncopetachycardiathromboembolismthrombophlebitisGlucose Thrombophlebitis, vasculitis.
Decreased carbohydrate and glucose tolerance, development of cushingoid state, glycosuria, hirsutismhypertrichosis, increased requirements for insulin or oral hypoglycemic agents in diabetesmanifestations of latent diabetes mellitusmenstrual irregularities, secondary adrenocortical and pituitary unresponsiveness particularly in times of stressGlucose Thrombophlebitis, as in traumaGlucose Thrombophlebitis, surgeryor illnesssuppression of growth in pediatric patients.
Fluid and electrolyte disturbances: Congestive heart failure in susceptible patients, fluid retention, hypokalemic alkalosis, Glucose Thrombophlebitis, potassium loss, sodium retention. Neurologic ]elevation in serum liver enzyme levels usually reversible upon discontinuationhepatomegalyGlucose Thrombophlebitis, increased appetite, nauseapancreatitispeptic ulcer with possible perforation and hemorrhageperforation of the small and large intestine particularly in patients with inflammatory bowel diseaseulcerative esophagitis.
Aseptic necrosis of femoral and humeral heads, calcinosis following intra- articular or intralesional useCharcot-like arthropathy, loss of muscle mass, muscle weakness, osteoporosispathologic fracture of long bones, post injection flare following intra-articular usesteroid myopathy, tendon rupture, vertebral compression fractures.
Convulsions, depressionemotional instability, euphoriaheadache, increased intracranial pressure with papilledema pseudotumor cerebri usually following discontinuation of treatment, insomniamood swings, neuritisneuropathyparesthesiapersonality changes, psychiatric disorders, vertigo.
Spinal cord infarction, paraplegiaquadriplegiacortical blindnessand stroke including brainstem have been reported after epidural administration of corticosteroids see WARNINGS: Exophthalmosglaucomaincreased intraocular pressureposterior subcapsular cataracts, rare instances of blindness associated with periocular injections. Abnormal fat deposits, decreased resistance to infectionhiccupsGlucose Thrombophlebitis, increased or decreased motility and number of spermatozoa, malaisemoon face, weight gain.
Kenalog 10 Injection Generic Name: Last reviewed on RxList: Kenalog 10 Injection Side Effects Center. Kenalog 10 Injection Consumer Information. Kenalog 10 Injection Professional Information.
Related Resources for Kenalog 10 Injection. Related Health Allergy Drugs: Understand Immunotherapy Painful Knees?
Sign up to bookmark this SPC already have an account? Find medicines with the same active ingredients. Find medicines from the same company. Qualitative and quantitative composition Glucose as monohydrate: For the full list of excipients, see section 6, Glucose Thrombophlebitis.
Pharmaceutical form Solution for infusion. Clear solution, free from visible particles. Supply of carbohydrate Glucose Thrombophlebitis or, as required, during parenteral nutrition.
Prevention and treatment of hypoglycaemia. Rehydration in case of water loss and dehydration states in patients with high carbohydrate need. Dilution Glucose Thrombophlebitis compatible medicinal products. The recommended doses in Table 1 serve as a guideline for an average adult with a body weight of approximately 70 kg. The infusion rate and volume depends on the age, weight, clinical and metabolic conditions of the patient, concomitant therapy and should be determined by a physician experienced in paediatric intravenous fluid therapy.
The recommended doses in Table 2 serve as a guideline for the paediatric population, as a function of body weight and age.
Dependant on the nature of the additive. The largest volumes within recommended dose should be administered in 24 hours to avoid haemodilution, Glucose Thrombophlebitis.
The maximum rate of administration should not exceed the patient's rate of glucose oxidation, as this may cause hyperglycaemia. Depending on the patient ' s clinical condition, a lower flow rate than recommended can be used in order to decrease the risk of undesirable osmotic diuresis. When the solution is used for dilution or delivery of compatible therapeutic additives for administration intravenously, the directions for use of the additive therapeutic substances will Glucose Thrombophlebitis the appropriate volumes for each therapy.
Administration is usually via a Glucose Thrombophlebitis or central vein, Glucose Thrombophlebitis. The osmolarity of a final admixed infusion solution must be taken into account when peripheral administration is considered. Please Glucose Thrombophlebitis section 3 for the information about the osmolarity of the solution, Glucose Thrombophlebitis.
A gradual increase of flow rate should be considered when starting administration of glucose-containing products. Precautions to be taken before handling or administering the medicinal product. The solution for infusion should be visually inspected before use. Parenteral drug products should be inspected visually for Glucose Thrombophlebitis matter and discoloration prior to administration, whenever solution and container permit. Use only if the solution is clear, without visible particles and if the container is undamaged.
Administer immediately following the insertion of infusion set. The solution should be administered with sterile equipment using an aseptic technique. The equipment should be primed with the solution in order to prevent air entering the system. Electrolyte supplementation may be indicated according to Glucose Thrombophlebitis clinical needs of the patient.
Additives may be introduced before infusion or during infusion through the appropriate port. When making additions, the final osmolarity of the mixture must be measured before administration. Administration of hyperosmolar solutions may cause venous irritation and phlebitis. Thorough and careful aseptic mixing of any additive is mandatory.
Solutions containing additives should be used immediately and not stored. The mixture obtained must be administered through a central or peripheral venous line depending on its final osmolarity. For information on incompatibilities and preparation of the product and additives, please see sections 6. Please see section 4. Treatment should be carried out under regular and careful surveillance.
Clinical and biological parameters, in particular plasma-glucose concentration, fluid balance and plasma electrolytes, should be monitored on regular basis and during treatment. The contra-indications related to any medicinal product that is added to the glucose solution should be considered. Depending on the volume and rate of infusion and depending on a patient's underlying clinical condition and capability to metabolize glucose, Glucose Thrombophlebitis, intravenous administration of glucose can cause: The above effects do not only result from the administration of electrolyte-free fluid but also from glucose administration.
Hyponatraemia can develop into acute hyponatraemic encephalopathy characterized by headache, nausea, seizures, Glucose Thrombophlebitis, lethargy, coma, cerebral oedema, and death. Children, the elderly, women, postoperative patients, patients with hypoxia and patients with central nervous system disease or psychogenic polydipsia are at particular risk for this complication. Clinical evaluation and periodic laboratory determinations may be necessary to monitor changes in fluid balance, electrolyte concentrations, Glucose Thrombophlebitis, and Glucose Thrombophlebitis balance during prolonged parenteral therapy or Glucose Thrombophlebitis the Glucose Thrombophlebitis of the patient or the rate of administration warrants such evaluation.
Particular caution is advised in patients at increased risk of water and electrolyte disturbances that could be aggravated by increased free water load, hyperglycaemia or possibly required insulin administration see below.
In case of prolonged administration or high glucose dose, care should be taken to avoid hypokalaemia by monitoring plasma potassium levels and administering a potassium supplement as appropriate. Special clinical monitoring is required at the beginning of any intravenous infusion. Monitor blood glucose closely as early hyperglycaemia has been associated with poor outcomes in patients with severe traumatic brain injury.
Solutions containing glucose should therefore be used with caution, Glucose Thrombophlebitis, if at all, in patients with known allergy to corn or corn products see section 4, Glucose Thrombophlebitis. Appropriate therapeutic countermeasures must be instituted as clinically indicated.
Thiamine deficiency and fluid retention may also develop, Glucose Thrombophlebitis. Careful monitoring and slowly increasing nutrient intakes while avoiding overfeeding can prevent these complications. The infusion rate and volume depends on the age, Glucose Thrombophlebitis, weight, clinical and metabolic conditions of the patient, Glucose Thrombophlebitis, concomitant therapy, and should be determined by a consulting physician experienced in paediatric intravenous fluid therapy.
In order to avoid potentially fatal over infusion of intravenous fluids to the neonate, special attention needs to be paid to the method of administration. When using a syringe pump to administer intravenous fluids or medicines to neonates, a bag of fluid Glucose Thrombophlebitis not be left connected to the syringe.
When using an infusion pump all clamps on the intravenous administration set must be closed before removing the administration set from the pump, or switching the pump off. This is required regardless of whether the Glucose Thrombophlebitis set has an anti free flow device. The intravenous infusion device and administration equipment must be frequently monitored.
Paediatric glycaemia related issues, Glucose Thrombophlebitis. Hypoglycaemia in the newborn can Glucose Thrombophlebitis prolonged seizures, coma and cerebral injury. Hyperglycaemia has been associated with intraventricular haemorrhage, late onset bacterial and fungal infection, retinopathy of prematurity, necrotizing enterocolitis, bronchopulmonary dysplasia, Glucose Thrombophlebitis, prolonged length of hospital stay, Glucose Thrombophlebitis, and death.
Dosage, rate, and duration of administration should be determined by a physician experienced in paediatric intravenous fluid therapy.
Risk of Air Embolism. Vented intravenous administration sets with the vent in the open position should not be used with flexible plastic containers. For method of administration and precautions to be taken before handling or administering the medicinal product, please see also section 4.
Concomitant administration of catecholamines and steroids decreases the glucose up-take. No interaction studies have been performed. Intrapartum maternal intravenous glucose infusion may result in foetal insulin production, with an associated risk of foetal hyperglycaemia and metabolic acidosis as well as rebound hypoglycaemia in the neonate.
Glucose solution can be used during pregnancy. However, caution should be exercised when glucose solution is used intrapartum.
There are no adequate data of the effect of Glucose on fertility. Glucose Thrombophlebitis, no effect on fertility is expected. There are no adequate data of using Glucose solution during lactation, Glucose Thrombophlebitis.
However, no effect on lactation is expected, Glucose Thrombophlebitis. Glucose solution can be used during lactation. Reporting suspected adverse reactions after authorisation of the medicinal product is important. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme. Severe hyperglycaemia and hyponatraemia may be fatal see sections 4.
Management of overdose is symptomatic and supportive, with appropriate monitoring, Glucose Thrombophlebitis. The pharmacodynamic properties of this solution are those of glucose, which forms the principal source of energy in cellular metabolism. Glucose is given as a source of carbohydrate, Glucose Thrombophlebitis, alone or, as required, in parenteral nutrition, Glucose Thrombophlebitis. Furthermore glucose solution for infusion allows hydric supplementation Glucose Thrombophlebitis ionic supplementation.
Glucose is metabolised via pyruvic or lactic acid to carbon dioxide and water with release of energy. The safety of potential additives should be considered separately. Incompatibility of the medicinal product to be added with the solution in Viaflo container must be assessed before its addition. In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products. The instructions for use of the medicinal product to be added must be consulted.
When a compatible medication is added to the Glucose Intravenous Infusion, the solution must be administered immediately. Those additives known Glucose Thrombophlebitis be incompatible should not be used. From a microbiological point of view, the diluted product must be used immediately unless dilution has taken place in controlled and validated aseptic conditions.
If not used immediately, in-use Glucose Thrombophlebitis times Glucose Thrombophlebitis conditions are the responsibility of the user. For storage conditions after dilution of the medicinal product, see section 6. When introducing additives to Glucose solution aseptic technique must be used. Do not remove unit from overwrap until ready for use. The inner bag maintains the sterility of the product.
Remove the Viaflo container from the overpouch just before use.